Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)

Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00536692

Enrollment

Unknown

Registered

2007-09-28

Start date

2007-09-30

Completion date

2008-04-30

Last updated

2008-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema

Keywords

macular edema, DME, diabetic, mecamylamine, Comentis

Brief summary

This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.

Interventions

DRUGmecamylamine

topical ocular drops

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* macular edema due to diabetic retinopathy

Exclusion criteria

* vision loss from other ocular disease * intraocular surgery within 3 months * intraocular anti-VEGF or steroids within 3 months * HbA1c \>12

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026